Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma

Journal of Endocrinology

Volumn 213, Issue 2, 2012, Pages 155-161

  Hantel, Constanze ^a   Lewrick, Felicitas ^b   Reincke, Martin ^a   Süss, Regine ^b   Beuschlein, Felix ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DOXORUBICIN; IMMUNOLIPOSOME; MACROGOL; PHOSPHATIDYLCHOLINE; SOMATOMEDIN C;

ADRENAL CORTEX CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; RECEPTOR, IGF TYPE 1;

EID: 84862063030     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0427     Document Type: Article

References (30)

1. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 91 2650-2655.
2. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037.
3. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E & Hammer GD 2009 Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 94 204-212.
4. Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R & Ellis LM 2007 Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Annals of Surgical Oncology 14 2838-2846.
5. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AN, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS et al. 2005 Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clinical Cancer Research 11 2063-2073.
6. Connelly MA & Williams DL 2003 SR-BI and cholesterol uptake into steroidogenic cells. Trends in Endocrinology and Metabolism 14 467-472.
7. Drummond DC, Meyer O, Hong K, Kirpotin DB & Papahadjopoulos D 1999 Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological Reviews 51 691-743.
8. Fottner C, Hoeflich A, Wolf E & Weber MM 2004 Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Hormone and Metabolic Research 36 397-405.
9. Gabizon AA 2002 Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. Journal of Drug Targeting 10 535-538.
10. Gabizon A, Dagan A, Goren D, Barenholz Y & Fuks Z 1982 Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Research 42 4734-4739.
11. Gabizon AA, Shmeeda H & Zalipsky S 2006 Pros and cons of the liposome platform in cancer drug targeting. Journal of Liposome Research 16 175-183.
12. Gantert M, Lewrick F, Adrian JE, Rössler J, Steenpass T, Schubert R & Peschka-Süss R 2008 Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors. Pharmacological Research 26 529-538.
13. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA & La Rocca RV 1990 Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Research 50 5488-5496.
14. Graf GA, Matveev SV & Smart EJ 1999 Class B scavenger receptors, caveolae and cholesterol homeostasis. Trends in Cardiovascular Medicine 9 221-225.
15. Hantel C, Lewrick F, Schneider S, Zwermann O, Perren A, Reincke M, Süss R & Beuschlein F 2010 Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency. Journal of Clinical Endocrinology and Metabolism 95 943-952.
16. Harrington KJ, Syrigos KN & Vile RJ 2002 Liposomally targeted cytotoxic drugs for the treatment of cancer. Journal of Pharmacy and Pharmacology 54 1573-1600.
17. Huwyler J, Drewe J & Krähenbuhl S 2008 Tumor targeting using liposomal antineoplastic drugs. International Journal of Nanomedicine 3 21-29.
18. Li SL, Kato J, Paz IB, Kasuya J & Fujita-Yamaguchi Y 1993 Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochemical and Biophysical Research Communications 196 92-98.
19. Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, Rückauer KD & Beuschlein F 2008 Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology 149 1314-1322.
20. Logie A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y & Gicquel C 1999 Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology 23 23-32.
21. Maeda H, Wu J, Sawa T, Matsumura Y & Hori K 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release 65 271-284.
22. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y & Bornstein SR 2004 The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews 25 309-340.
23. Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL & de Alava E 2006 Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clinical Cancer Research 12 3532-3540.
24. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C et al. 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. PNAS 88 11460-11464.
25. Sofou S & Sgouros G 2008 Antibody-targeted liposomes in cancer therapy and imaging. Expert Opinion on Drug Delivery 5 189-204. (doi:10.1517/ 17425247.5.2.189)
26. Tardi P, Bally MB & Harasym TO 1998 Clearance properties of liposomes involving conjugated proteins for targeting. Advanced Drug Delivery Reviews 32 99-118.
27. Theodoulou M & Hudis C 2004 Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 100 2052-2063.
28. Toretsky JA, Thakar M, Eskenazi AE & Frantz CN 1999 Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Research 59 5745-5750.
29. Weber MM, Fottner C & Wolf E 2000 The role of the insulin-like growth factor system in adrenocortical tumourigenesis. European Journal of Clinical Investigation 30 (Suppl 3) 69-75.
30. Williams DL, Wong JS & Hamilton RL 2002 SR-BI is required for microvillar channel formation and the localization of HDL particles to the surface of adrenocortical cells in vivo. Journal of Lipid Research 43 544-549.